Clinical Trial

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases
Trial Details
NCT Number NCT07677293
Lead Sponsor Peking University
Conditions Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Enrollment 332 participants
Start Date 2026-06-26
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-30